UO > Research > Projects & Grants
Projects & Grants
|Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive
|Main solver||MUDr. Renáta Poláčková|
|Period||1/2016 - 12/2020|
|Anotation||Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in
the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe.
Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults.
Despite hypothermia and neonatal intensive care, 45-50% of affected children die or suffer from long-term
neurodevelopmental impairment. Additional neuroprotective interventions, beside hypothermia, are warranted to further
improve their outcome.
Allopurinol is a xanthine oxidase inhibitor and reduces the production of oxygen radicals and brain damage in experimental,
animal, and early human studies of ischemia and reperfusion.
This project aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to near-term infants
with HIE in addition to hypothermic treatment.
Beyond this primary objective, the project will provide information on the effect of hypothermia on pharmacokinetics of drugs
with a similar metabolism as allopurinol in neonates. Furthermore it will give the opportunity to further develop and validate
biomarkers for neonatal brain injury using advanced magnetic resonance imaging, biochemistry, and
electroencephalogramms, which will then be available for future studies testing neuroprotective interventions. Finally, this
trial will extend our knowledge about incidence of and risk factors for perinatal asphyxia and HIE possibly enabling
generation of more preventive strategies for the future.|